Sophiris Bio Inc (NASDAQ:SPHS) shares saw unusually-strong trading volume on Monday . Approximately 1,944,823 shares traded hands during trading, an increase of 18% from the previous session’s volume of 1,650,252 shares.The stock last traded at $3.24 and had previously closed at $2.66.

A number of research analysts have recently issued reports on the stock. Maxim Group reiterated a “buy” rating and issued a $4.00 target price on shares of Sophiris Bio in a research note on Thursday, March 24th. Echelon Wealth Partners reiterated a “buy” rating and issued a $5.00 target price on shares of Sophiris Bio in a research note on Friday, June 10th.

The stock’s 50-day moving average price is $1.93 and its 200-day moving average price is $1.64. The stock’s market capitalization is $64.95 million.

Sophiris Bio (NASDAQ:SPHS) last issued its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.06. On average, equities analysts forecast that Sophiris Bio Inc will post ($0.73) EPS for the current fiscal year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.